Skip to main content
Erschienen in: Clinical Rheumatology 8/2014

01.08.2014 | Brief Report

Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients’ opinion

verfasst von: I. M. Markusse, G. Akdemir, T. W. J. Huizinga, C. F. Allaart

Erschienen in: Clinical Rheumatology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Clinical trials have shown that in patients with long-standing low disease activity, tapering and/or stopping antirheumatic medication is a realistic option. The objective of this study is to explore patients’ opinion about tapering and discontinuing antirheumatic drugs. This qualitative study is based on interviews with 20 patients with rheumatoid arthritis (RA) about RA treatment and treatment discontinuation through structured interviewing. Interviews were tape-recorded, transcribed verbatim, and screened by three assessors independently for meaning units. Not only positive emotions about drug discontinuation such as hope, happiness, and relief, but also fear and disappointment were mentioned. Some patients expect that drug discontinuation will be possible in other patients and/or themselves, while others do not expect this. The concept of increase in disease activity after discontinuing medication was mentioned, and while patients expect that disease activity will decrease again after restarting medication, they expect that this will take (too much) time. Positive emotions about the option to taper and discontinue antirheumatic medication, with negative expectations is a common combination in these RA patients. In particular, patients expect that disease activity will flare and that improvement upon restarting medication will take time. Patients’ expectations and feelings should be addressed before drug tapering is attempted in a clear strategy of continued monitoring of disease activity.
Literatur
1.
Zurück zum Zitat Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286–1291PubMedCentralPubMedCrossRef Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286–1291PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Nawata M, Saito K, Nakayamada S, Tanaka Y (2008) Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 18(5):460–464PubMedCrossRef Nawata M, Saito K, Nakayamada S, Tanaka Y (2008) Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 18(5):460–464PubMedCrossRef
3.
Zurück zum Zitat ten Wolde S, Breedveld FC, Hermans J et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347(8998):347–352PubMedCrossRef ten Wolde S, Breedveld FC, Hermans J et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347(8998):347–352PubMedCrossRef
4.
Zurück zum Zitat van den Broek M, Klarenbeek NB, Dirven L et al (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 70(8):1389–1394PubMedCrossRef van den Broek M, Klarenbeek NB, Dirven L et al (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 70(8):1389–1394PubMedCrossRef
5.
Zurück zum Zitat van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(6):914–921PubMedCrossRef van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(6):914–921PubMedCrossRef
6.
Zurück zum Zitat Klarenbeek NB, van der Kooij SM, Guler-Yuksel M et al (2011) Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 70(2):315–319PubMedCrossRef Klarenbeek NB, van der Kooij SM, Guler-Yuksel M et al (2011) Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 70(2):315–319PubMedCrossRef
7.
Zurück zum Zitat Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H (1999) The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technol Assess 3(3):1–96PubMed Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H (1999) The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technol Assess 3(3):1–96PubMed
8.
Zurück zum Zitat Kvale S (1996) Interviews: an introduction to qualitative research interviewing. Sage, California, USA Kvale S (1996) Interviews: an introduction to qualitative research interviewing. Sage, California, USA
9.
Zurück zum Zitat Jones K (2002) The turn to a narrative knowing of persons: one method explored. Nursing Times Research 8:60–71CrossRef Jones K (2002) The turn to a narrative knowing of persons: one method explored. Nursing Times Research 8:60–71CrossRef
10.
Zurück zum Zitat Francis JJ, Johnston M, Robertson C et al (2010) What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health 25(10):1229–1245PubMedCrossRef Francis JJ, Johnston M, Robertson C et al (2010) What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health 25(10):1229–1245PubMedCrossRef
11.
Zurück zum Zitat Suter LG, Fraenkel L, Holmboe ES (2006) What factors account for referral delays for patients with suspected rheumatoid arthritis? Arthritis Rheum 55(2):300–305PubMedCrossRef Suter LG, Fraenkel L, Holmboe ES (2006) What factors account for referral delays for patients with suspected rheumatoid arthritis? Arthritis Rheum 55(2):300–305PubMedCrossRef
12.
Zurück zum Zitat Stamm TA, Cieza A, Coenen M et al (2005) Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for rheumatoid arthritis from the patient perspective: a qualitative study. Arthritis Rheum 53(3):431–439PubMedCrossRef Stamm TA, Cieza A, Coenen M et al (2005) Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for rheumatoid arthritis from the patient perspective: a qualitative study. Arthritis Rheum 53(3):431–439PubMedCrossRef
13.
Zurück zum Zitat Detert J, Bastian H, Listing J et al (2013) Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72(6):844–850PubMedCrossRef Detert J, Bastian H, Listing J et al (2013) Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72(6):844–850PubMedCrossRef
14.
Zurück zum Zitat Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices. Arthritis Rheum 56(7):2135–2142PubMedCrossRef Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices. Arthritis Rheum 56(7):2135–2142PubMedCrossRef
15.
Zurück zum Zitat Mugunthan K, McGuire T, Glasziou P (2011) Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract 61(590):e573–e578PubMedCentralPubMedCrossRef Mugunthan K, McGuire T, Glasziou P (2011) Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract 61(590):e573–e578PubMedCentralPubMedCrossRef
Metadaten
Titel
Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients’ opinion
verfasst von
I. M. Markusse
G. Akdemir
T. W. J. Huizinga
C. F. Allaart
Publikationsdatum
01.08.2014
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 8/2014
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2500-y

Weitere Artikel der Ausgabe 8/2014

Clinical Rheumatology 8/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.